

10/256,198

=> d his

(FILE 'HOME' ENTERED AT 11:06:31 ON 16 NOV 2005)

FILE 'REGISTRY' ENTERED AT 11:06:41 ON 16 NOV 2005

L1 STRUCTURE UPLOADED

L2 14 S L1

L3 STRUCTURE UPLOADED

L4 9 S L3

L5 252 S L1 SSS FUL

L6 138 S L3 SUB=L5 FUL


FILE 'CAPLUS' ENTERED AT 11:09:23 ON 16 NOV 2005

L7 14 S L6

=> d l1

L1 HAS NO ANSWERS

L1 STR




Structure attributes must be viewed using STN Express query preparation.

=> d l3

L3 HAS NO ANSWERS

L3 STR



10/256,198

Structure attributes must be viewed using STN Express query preparation.

=> d ibib abs hitstr total

17 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2005:730050 CAPLUS

DOCUMENT NUMBER: 143:367274

TITLE: Design and Synthesis of Tricyclic Corticotropin-Releasing Factor-1 Antagonists

AUTHOR(S): Gross, Raymond S.; Guo, Zhiqiang; Dyck, Brian; Coon, Tim; Huang, Charles Q.; Lowe, Richard F.; Marinkovic, Dragan; Moorjani, Manisha; Nelson, Jodene; Zamani-Kord, Said; Grigoriadis, Dimitri E.; Hoare, Sam R. J.; Crowe, Paul D.; Bu, Jane Han; Haddach, Mustapha; McCarthy, James; Saunders, John; Sullivan, Robert; Chen, TaKung; Williams, John P.

CORPORATE SOURCE: Departments of Medicinal Chemistry, Pharmacology and Lead Discovery and Preclinical Development, Neurocrine Biosciences, San Diego, CA, 92130, USA

SOURCE: Journal of Medicinal Chemistry (2005), 48(18), 5780-5793

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


AB Antagonists of the corticotropin-releasing factor (CRF) neuropeptide should prove to be effective in treating stress and anxiety-related disorders. In an effort to identify antagonists with improved physicochem. properties, new tricyclic CRF1 antagonists were designed, synthesized, and tested for biol. activity. As a result of studies aimed at establishing a relationship between structure and CRF1 binding affinity, NBI 35965 [i.e., (7S)-6-(cyclopropylmethyl)-2-(2,4-dichlorophenyl)-7-ethyl-7,8-dihydro-4-methyl-6H-1,3,6,8a-tetraazaacenaphthylene (I)] was identified as a high-affinity antagonist with a pKi value of 8.5. I proved to be a functional CRF1 antagonist with pIC50 values of 7.1 and 6.9 in the in vitro CRF-stimulated cAMP accumulation and ACTH production assays, resp., and I also reduced CRF or stress induced ACTH production in vivo.

IT 268547-48-4P 268547-49-5P 866141-71-1P
866141-72-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of 1,3,6,8a-tetraazaacenaphthylene derivs. and study of their activity as corticotropin-releasing factor-1 antagonists)

RN 268547-48-4 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
(CA INDEX NAME)

RN 268547-49-5 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl-
(9CI) (CA INDEX NAME)



RN 866141-71-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 866141-72-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT **242128-98-9**

RL: PAC (Pharmacological activity); BIOL (Biological study)
(preparation of 1,3,6,8a-tetraazaacenaphthylene derivs. and study of their activity as corticotropin-releasing factor-1 antagonists in comparison with antalarimin)

RN 242128-98-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

31

THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

ANSWER 2 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:689677 CAPLUS

DOCUMENT NUMBER: 139:332356

TITLE: Synthesis of 1-methyl-3-phenylpyrazolo[4,3-b]pyridines via a methylation of 4-phthalimino-3-phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists

AUTHOR(S): Huang, Charles Q.; Wilcoxon, Keith; McCarthy, James R.; Haddach, Mustaph; Grigoriadis, Dimitri; Chen, Chen
CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(19), 3371-3374

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:332356

AB 1-Methyl-3-phenylpyrazolo[4,3-b]pyridines were synthesized via a cyclization reaction of 1-methyl-4-amino-3-phenylpyrazoles with Et acetoacetate. Optimization of this series of compds. resulted in CRF1 antagonists with subnanomolar binding affinity. Compds. bearing a polar group such as methoxy or hydroxy were also found to be very active.


IT 242128-81-0P 242128-82-1P 242128-84-3P
242128-86-5P 242128-89-8P 242128-98-9P
242129-06-2P 242129-20-0P 617709-87-2P
617709-90-7P 617709-95-2P 617709-97-4P
617709-99-6P 617710-01-7P 617710-02-8P
617710-03-9P 617710-04-0P 617710-05-1P
617710-06-2P 617710-07-3P 617710-08-4P
617710-09-5P 617710-10-8P 617710-11-9P
617710-12-0P 617710-13-1P 617710-14-2P
617710-15-3P 617710-16-4P 617710-17-5P
617710-18-6P 617710-19-7P 617710-20-0P
617710-21-1P 617710-22-2P 617710-23-3P
617710-24-4P 617710-25-5P 617710-26-6P
617710-27-7P 617710-28-8P 617710-29-9P
617710-30-2P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(structure-activity relationship and preparation of phenylpyrazolo pyridines via a methylation of phthalimino phenylpyrazoles and optimization toward highly potent corticotropin-releasing factor type-1 antagonists)


RN 242128-81-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242128-82-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-1,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242128-84-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-N,1,5-trimethyl- (9CI) (CA INDEX NAME)




RN 242128-86-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N,1,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242128-89-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242128-98-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-06-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methylphenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-20-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4,6-dimethylphenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617709-87-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-ethyl-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 617709-90-7 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-N-ethyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617709-95-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 617709-97-4 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1,5-dimethyl-N-(2-methylpropyl)- (9CI) (CA INDEX NAME)



RN 617709-99-6 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-

dichlorophenyl)-1,5-dimethyl-N-pentyl- (9CI) (CA INDEX NAME)




RN 617710-01-7 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-N-hexyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-02-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-03-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-ethyl-1,5-dimethyl-N-pentyl- (9CI) (CA INDEX NAME)




RN 617710-04-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-1,5-dimethyl-N-pentyl-N-propyl- (9CI) (CA INDEX NAME)




RN 617710-05-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-1,5-dimethyl-N-pentyl- (9CI) (CA INDEX NAME)




RN 617710-06-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-(1-ethylpropyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-07-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methoxyphenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-08-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-1,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)




RN 617710-09-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(4-chlorophenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-10-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-ethyl-N-(2-methoxyethyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-11-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-ethyl-N-(2-methoxyethyl)-5-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-12-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-5-methyl-N-(1-methylethyl)-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-13-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-5-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-14-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-5-methyl-N-(2-methylpropyl)-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-15-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-5-methyl-N-pentyl-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-16-4 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-hexyl-N-(2-methoxyethyl)-5-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-17-5 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N,N-bis(2-methoxyethyl)-5-methyl-1-propyl- (9CI) (CA INDEX NAME)



RN 617710-18-6 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-ethyl-N-(3-methoxypropyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-19-7 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 617710-20-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-(3-methoxypropyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 617710-21-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-5-methyl-N-[2-(methylthio)ethyl]-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-22-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-5-methyl-1-propyl-N-[(tetrahydro-2-furanyl)methyl]- (9CI) (CA INDEX NAME)




RN 617710-23-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-5-methyl-
N-[(1-methyl-2-pyrrolidinyl)methyl]-1-propyl- (9CI) (CA INDEX NAME)




RN 617710-24-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-5-methyl-
1-propyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)




RN 617710-25-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-5-methyl-1-propyl-N-[2-(4-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 617710-26-6 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-5-methyl-1-propyl-N-[2-(2-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)




RN 617710-27-7 CAPLUS

CN Phenol, 4-[[[3-(2,4-dichlorophenyl)-5-methyl-1-propyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]methyl]- (9CI) (CA INDEX NAME)




RN 617710-28-8 CAPLUS

CN Phenol, 4-[[[3-(2,4-dichlorophenyl)-5-methyl-1-propyl-1H-pyrazolo[4,3-b]pyridin-7-yl]propylamino]methyl]- (9CI) (CA INDEX NAME)




RN 617710-29-9 CAPLUS

CN Ethanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1-propyl-1H-pyrazolo[4,3-b]pyridin-7-yl]ethylamino]- (9CI) (CA INDEX NAME)



RN 617710-30-2 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1-propyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

10

THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

LE ANSWER 3 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:689676 CAPLUS

DOCUMENT NUMBER: 139:358013

TITLE: Synthesis of 3-phenylpyrazolo[4,3-b]pyridines via a convenient synthesis of 4-amino-3-arylpyrazoles and SAR of corticotropin-releasing factor receptor type-1 antagonists

AUTHOR(S): Wilcoxon, Keith; Huang, Charles Q.; McCarthy, James R.; Grigoriadis, Dimitri E.; Chen, Chen

CORPORATE SOURCE: Department of Medicinal Chemistry and Department of Pharmacology, Neurocrine Biosciences, Inc., San Diego, CA, 92121, USA

SOURCE: Bioorganic & Medicinal Chemistry Letters (2003), 13(19), 3367-3370

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier Science B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 139:358013

AB 3-Phenylpyrazolo[4,3-b]pyridines were synthesized via a cyclization of corresponding 4-amino-3-phenylpyrazoles with Et acetoacetate. These compds. were potent CRF1 antagonists. The 2-alkylpyrazolo[4,3-b]pyridines were more polar but less active than the corresponding 1-alkyl isomers.

IT 242128-80-9P 242128-82-1P 242128-87-6P

242128-89-8P 242128-91-2P 242128-92-3P

242128-93-4P 242128-94-5P 242128-95-6P

242128-96-7P 242128-97-8P 242128-99-0P

242129-00-6P 242129-01-7P 242129-02-8P

242129-03-9P 242129-04-0P 242129-05-1P

242129-12-0P 242129-14-2P 242129-27-7P

242129-29-9P 617710-02-8P 622400-32-2P

622400-33-3P 622400-34-4P 622400-35-5P


622400-36-6P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(synthesis of 3-phenylpyrazolo[4,3-b]pyridines and SAR of corticotropin-releasing factor receptor type-1 antagonists)


RN 242128-80-9 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242128-82-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-1,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242128-87-6 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 242128-89-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242128-91-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-1-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242128-92-3 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-2-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242128-93-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-1-propyl- (9CI) (CA INDEX NAME)




RN 242128-94-5 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-2-propyl- (9CI) (CA INDEX NAME)




RN 242128-95-6 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 242128-96-7 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 242128-97-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242128-99-0 CAPLUS


CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 242129-00-6 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-01-7 CAPLUS
 CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-2-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-02-8 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-

5-methyl- (9CI) (CA INDEX NAME)




RN 242129-03-9 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-04-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N,1-diethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-05-1 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N,2-diethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-12-0 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methylphenyl)-2-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-14-2 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(cyclopropylmethyl)-2-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-27-7 CAPLUS


CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 2,5-dimethyl-3-phenyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242129-29-9 CAPLUS
 CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



RN 617710-02-8 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 622400-32-2 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-N,5-dimethyl- (9CI) (CA INDEX NAME)




RN 622400-33-3 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 622400-34-4 CAPLUS


CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-[2-(4-methoxyphenyl)ethyl]-2,5-dimethyl- (9CI) (CA INDEX NAME)



RN 622400-35-5 CAPLUS


10/256,198

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(4-chlorophenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 622400-36-6 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methoxyphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

23

THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:196945 CAPLUS

DOCUMENT NUMBER: 138:221599

TITLE: Synthesis of tricyclic fused compounds (e.g., fused tricyclic pyrimidines) as CRF receptor antagonists

INVENTOR(S): Haddach, Mustapha; Dyck, Brian P.; Huang, Charles Q.; Nelson, Jodie; Guo, Zhiqiang; McCarthy, James R.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: U.S., 85 pp., Cont.-in-part of U.S. Ser. No. 439,840.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English




FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6531475	B1	20030311	US 2000-574751	20000518
US 6514982	B1	20030204	US 1999-439840	19991112
WO 2001087885	A1	20011122	WO 2001-US16048	20010517
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
ZA 2001004441	A	20020530	ZA 2001-4441	20010530
US 2004087589	A1	20040506	US 2003-339780	20030108
US 2004157851	A1	20040812	US 2003-701394	20031104
PRIORITY APPLN. INFO.:			US 1998-191073	B2 19981112
			US 1999-370837	B2 19990809
			US 1999-401364	B2 19990921
			US 1999-439840	A2 19991112
			US 2000-574751	A 20000518
			US 2003-339780	B1 20030108

OTHER SOURCE(S): MARPAT 138:221599

GI



AB Title compds. I [$n = 1-2$; A, Z = N, C, CH; B = N, CR₃, with the proviso that at least one of A, B and Z = N; A, B and Z are not all nitrogen; and either A-B or B-Z is a double bond; X = N, C(H, alkyl, halo); Ar = (substituted) aryl, (substituted) heteroaryl; R = alkyl, alkylidenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; $m = 0-3$; R₁ = alkyl, sulfonyl; R₂ = H, (halo)alkyl, CN; R₃ = H, (halo)alkyl] were prepared For instance, 2,4-dichloro-6-methyl-3-(vinylcarbonyl)pyridine (preparation given) was reacted with 4-heptylamine (EtOH, 60°C, 16 h) afforded regioisomer II isolated by chromatog. II was condensed with the 2,4-dichlorophenylhydrazone of benzaldehyde (TsOH, 140°C, 5 min) to give the tricyclic fused pyrazole III. Certain examples I had $K_i < 1 \mu\text{M}$ for the CRF receptor. I have utility in the treatment of disorders manifesting hypersecretion of CRF, such as stroke.

IT **268547-48-4P 268547-49-5P 268547-50-8P**


268547-55-3P 268547-68-8P 374800-50-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(intermediate; synthesis of tricyclic fused compds. (e.g., fused tricyclic pyrimidines) as CRF receptor antagonists)

RN 268547-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
(CA INDEX NAME)




RN 268547-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl-
(9CI) (CA INDEX NAME)


RN 268547-50-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 268547-55-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(1-butylpentyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 268547-68-8 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-


10/256,198

7-yl]amino]- (9CI) (CA INDEX NAME)



RN 374800-50-7 CAPLUS

CN Benzenemethanol, α -[[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

24

THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:92404 CAPLUS

DOCUMENT NUMBER: 138:137328

TITLE: Preparation of tricyclic compounds as CRF receptor antagonists

INVENTOR(S): Haddach, Mustapha; Dyck, Brian P.; Huang, Charles Q.; Nelson, Jodie; Guo, Zhiqiang; McCarthy, James R.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: U.S., 78 pp., Cont.-in-part of U.S. Ser. No. 401,364, abandoned.

CODEN: USXXAM

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6514982	B1	20030204	US 1999-439840	19991112
ES 2180338	T3	20030201	ES 1999-960363	19991112
PT 1129091	T	20030228	PT 1999-960363	19991112
US 6531475	B1	20030311	US 2000-574751	20000518
ZA 2001004441	A	20020530	ZA 2001-4441	20010530
US 2004087589	A1	20040506	US 2003-339780	20030108
US 2004157851	A1	20040812	US 2003-701394	20031104
PRIORITY APPLN. INFO.:			US 1998-191073	B2 19981112
			US 1999-370837	B2 19990809
			US 1999-401364	B2 19990921
			US 1999-439840	A2 19991112
			US 2000-574751	A1 20000518
			US 2003-339780	B1 20030108

OTHER SOURCE(S): MARPAT 138:137328


GI




AB The title compds. [I; n = 1-2; A, C = N, C, CH; B = N, CR₃; with the provisos that at least one of A, B and C = N; A, B and C are not all N; and either A-B or B-C is a double bond; X = N, CH; Ar = (un)substituted aryl, heteroaryl; R = alkyl, alkylidenyl, arylalkyl, heteroarylalkyl; m =

0-3; R1 = C(H)O,1R4R5, SO2R5; R2 = H, alkyl; R3 = H, alkyl, haloalkyl; R4 = H, alkyl, halo, etc.; R5 = -YZR6; (un)substituted alkanediyl, a direct bond; Z = NH, O, S, etc.; R6 = H, alkyl, aryl, etc.] which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke, depression, and anxiety, were prepared E.g., a multi-step synthesis of II which showed Ki of < 250 nM against CRF receptor binding, was given.


- IT **268547-48-4P**, 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- **268547-49-5P**, 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl- **268547-50-8P**, 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-propylbutyl)- **268547-55-3P**, 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(1-butylpentyl)-3-(2,4-dichlorophenyl)-5-methyl- **268547-68-8P**, 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]-
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of tricyclic compds. as CRF receptor antagonists)
 RN 268547-48-4 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
 (CA INDEX NAME)



- RN 268547-49-5 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




- RN 268547-50-8 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 268547-55-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(1-butylpentyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 268547-68-8 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




REFERENCE COUNT:

35

THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN
 ACCESSION NUMBER: 2002:637678 CAPLUS
 DOCUMENT NUMBER: 137:169551
 TITLE: Tricyclic CRF receptor antagonists
 INVENTOR(S): Haddach, Mustapha
 PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA
 SOURCE: PCT Int. Appl., 37 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002064592	A1	20020822	WO 2001-US49906	20011221
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002128265	A1	20020912	US 2001-36752	20011221
US 6583143	B2	20030624		
EP 1345938	A1	20030924	EP 2001-271065	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004518731	T2	20040624	JP 2002-564523	20011221
US 2003130283	A1	20030710	US 2002-313096	20021204
PRIORITY APPLN. INFO.:				
			US 2000-258685P	P 20001228
			US 2001-36752	A1 20011221
			WO 2001-US49906	W 20011221
OTHER SOURCE(S): MARPAT 137:169551				
GI				



AB Tricyclic triazines I [X = N, CR3; Y = N, CR4; R1 = (un)substituted alkyl, NH2, aryl, heteroaryl; R2 = H, alkyl, alkoxy, thioalkyl, haloalkyl; R3 = H, alkyl, halo, haloalkyl; R4 = H, halogen, alkyl, alkoxy, thioalkyl, haloalkyl, amino; R5 = H, (un)substituted alkyl, aryl, heteroaryl; R6 = H, (un)substituted alkyl, NH2, OH, SH, aryl, heteroaryl] were prepared for use as CRF receptor antagonists in the treatment of diseases, such as stroke (no data). Thus, I [R1 = Br, R2, R6 = Me, R5 = H, X = CH, Y = N] was

treated with BrCHPr2 and 2,4-Me(MeO)C6H3B(OR)2 [R2 = CMe2CMe2] to give I
[R1 = 2,4-Me(MeO)C6H3, R2, R6 = Me, R5 = CHPr2, X = CH, Y = N].


IT **268547-48-4P 268547-49-5P 448964-61-2P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of pyridopyrazolotriazines as CRF receptor antagonists)


RN 268547-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
(CA INDEX NAME)




RN 268547-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl-
(9CI) (CA INDEX NAME)



RN 448964-61-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 3-(2,4-dichlorophenyl)-7-hydrazino-5-methyl-
(9CI) (CA INDEX NAME)



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ANSWER 7 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:184863 CAPLUS

DOCUMENT NUMBER: 136:221516

TITLE: Hair growth stimulants containing CRF1 receptor antagonists

INVENTOR(S): Ikeda, Akiko; Okuyama, Shigeru; Shibasaki, Tamotsu; Kawana, Seiji; Kaneko, Katsumi

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 39 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002019975	A1	20020314	WO 2001-JP7537	20010831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG AU 2001084417 A5 20020322 AU 2001-84417 20010831 PRIORITY APPLN. INFO.: JP 2000-269291 A 20000905 WO 2001-JP7537 W 20010831				

OTHER SOURCE(S): MARPAT 136:221516


AB Disclosed are hair growth stimulants containing a corticotropin release factor (CRF) 1 receptor antagonist as the active ingredient. A CRF1 receptor antagonist 2-[N-(2-methylthio-4-isopropylphenyl)-N-ethylamino]-4-[4-(3-fluorophenyl)-1,2,3,6-tetrahydropyridine-1-yl]-6-methylpyrimidine showed keratinocyte cell proliferation promoting effect in cultured human epidermal keratinocyte cells.

IT 242128-80-9

RL: COS (Cosmetic use); BIOL (Biological study); USES (Uses)
(hair growth stimulants containing CRF1 receptor antagonists)

RN 242128-80-9 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

12

THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 8 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2002:31438 CAPLUS

DOCUMENT NUMBER: 136:102370

TITLE: Preparation of tetrahydropyridine or piperidine heterocyclic derivatives and their affinity for CRF receptors

INVENTOR(S): Nakazato, Atsuro; Kumagai, Toshihito; Okubo, Taketoshi; Kameo, Kazuya

PATENT ASSIGNEE(S): Taisho Pharmaceutical Co., Ltd., Japan

SOURCE: PCT Int. Appl., 91 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002002549	A1	20020110	WO 2001-JP5806	20010704
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2412287	AA	20020110	CA 2001-2412287	20010704
AU 2001069437	A5	20020114	AU 2001-69437	20010704
EP 1299378	A1	20030409	EP 2001-947819	20010704
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012166	A	20030902	BR 2001-12166	20010704
JP 2004502685	T2	20040129	JP 2002-507801	20010704
TW 591022	B	20040611	TW 2001-90116391	20010704
EE 200300007	A	20040816	EE 2003-7	20010704
CN 1535968	A	20041013	CN 2004-10033876	20010704
ZA 2002010041	A	20031211	ZA 2002-10041	20021211
BG 107374	A	20040930	BG 2002-107374	20021211
NO 2002006125	A	20030204	NO 2002-6125	20021219
US 2004034061	A1	20040219	US 2003-311277	20030825
US 6852732	B2	20050208		
US 2005009874	A1	20050113	US 2004-912185	20040806
PRIORITY APPLN. INFO.:			JP 2000-204021	A 20000705
			JP 2000-270535	A 20000906
			WO 2000-JP5806	W 20000704
			WO 2001-JP5806	W 20010704
			US 2003-311277	A3 20030825

OTHER SOURCE(S): MARPAT 136:102370

AB Tetrahydropyridine or piperidine heterocyclic derivs. with high affinity for CRF receptors were prepared E.g., 5-(4-carbamoyl-1,2,3,6-tetrahydropyridin-1-yl)-2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole was prepared by bromination of 2-(N-ethyl-2,4-dichloroanilino)-4-methylthiazole hydrochloride, followed by reaction with 5-carbamoyl-1,2,3,6-tetrahydropyridine hydrochloride.

IT 388122-98-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU

(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of tetrahydropyridine or piperidine heterocyclic derivs. and
their affinity for CRF receptors)

RN 388122-98-3 CAPLUS

CN 4-Pyridinecarboxamide, 1-[3-(2,4-dichlorophenyl)-2,5-dimethyl-2H-
pyrazolo[4,3-b]pyridin-7-yl]-1,2,3,6-tetrahydro- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

11

THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

10/256,198

L7 ANSWER 9 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:851167 CAPLUS

DOCUMENT NUMBER: 135:371753

TITLE: Preparation of tricyclic heteroaromatics as CRF receptor antagonists

INVENTOR(S): Haddach, Mustapha; Williams, John P.; Marinkovic, Dragan; Bu, Jane H.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 54 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087892	A1	20011122	WO 2001-US16202	20010518
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
US 2002049203	A1	20020425	US 2001-861195	20010518
US 6440960	B2	20020827		
EP 1287002	A1	20030305	EP 2001-937569	20010518
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003533530	T2	20031111	JP 2001-584286	20010518
US 2003055050	A1	20030320	US 2002-123076	20020411
PRIORITY APPLN. INFO.:			US 2000-205607P	P 20000518
			US 2000-205611P	P 20000518
			US 2000-205614P	P 20000518
			US 2001-861195	A1 20010518
			WO 2001-US16202	W 20010518

OTHER SOURCE(S): MARPAT 135:371753
GI



AB Title compds. [I; A = N or CH; B = N or CR4; R = H or 1-3 of alkyl, alkoxy(carbonyl), aryl, etc.; R2 = H, (halo)alkyl, alkoxy, etc.; X = N or CR3; R3 = H, halo, (halo)alkyl; R4 = H, halo, alkyl, alkoxy, etc.; Y = O or SO0-2; Z = NR1 or CHR1; R1 = (un)substituted alkyl or -(hetero)aryl; dashed line = optional bond] were prepared. Thus, pyrazolopyridine II (R5 = R6 = H) was condensed with 2-ethoxymethyloxirane and the product cyclized to give II [R5R6 = CH(CH2OEt)CH2]. Data for biol. activity of I were given.


IT **268547-48-4 268547-49-5**

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of tricyclic heteroaroms. as CRF receptor antagonists)


RN 268547-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
(CA INDEX NAME)



RN 268547-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




IT **374632-46-9P 374632-47-0P**

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of tricyclic heteroaroms. as CRF receptor antagonists)


RN 374632-46-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine-1-ethanol, 3-(2,4-dichlorophenyl)-α-(ethoxymethyl)-7-hydroxy-5-methyl- (9CI) (CA INDEX NAME)



RN 374632-47-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-1-(2-chloroethyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




IT **374632-50-5P**

RL: BYP (Byproduct); PREP (Preparation)

(regioisomeric byproduct in the preparation of tricyclic heteroaroms. as CRF receptor antagonists)

RN 374632-50-5 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridine, 7-chloro-2-(2-chloroethyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2001:851160 CAPLUS

DOCUMENT NUMBER: 136:6001

TITLE: Synthesis of tricyclic (e.g., fused tricyclic pyrimidines) as crf receptor antagonists

INVENTOR(S): Haddach, Mustapha; Dyck, Brian P.; Huang, Charles Q.; Nelson, Jodie; Guo, Zhiqiang; McCarthy, James R.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 147 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001087885	A1	20011122	WO 2001-US16048	20010517
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6531475	B1	20030311	US 2000-574751	20000518
PRIORITY APPLN. INFO.:			US 2000-574751	A 20000518
			US 1998-191073	B2 19981112
			US 1999-370837	B2 19990809
			US 1999-401364	B2 19990921
			US 1999-439840	A2 19991112
OTHER SOURCE(S):	MARPAT 136:6001			
GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [n = 1 - 2; A, Z = N, C, CH; B = N, CR3, with the proviso that at least one of A, B and Z = N; A, B and Z are not all nitrogen; and either A-B or B-Z is a double bond; X = N, C(H, alkyl, halo); Ar = (substituted)aryl, (substituted)heteroaryl; R = alkyl, alkylidenyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl; m = 0 - 3; R1 = alkyl, sulfonyl; R2 = H, (halo)alkyl, CN; R3 = H, (halo)alkyl] were prepared. For instance, 2,4-dichloro-6-methyl-3-(vinylcarbonyl)pyridine (preparation given) was reacted with 4-heptylamine (EtOH, 60°C, 16 h) and regioisomer II isolated by chromatog. II was condensed with the 2,4-dichlorophenylhydrazine of benzaldehyde (TsOH, 140°C, 5 min) to give pyrazole III. Certain examples I had Ki < 1 µM for the CRF receptor. I have utility in the treatment of disorders manifesting hypersecretion of CRF, such as stroke, depression and anxiety.

IT 268547-48-4P 268547-49-5P 268547-50-8P


268547-55-3P 268547-68-8P 374800-50-7P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; synthesis of tricyclic (e.g., fused tricyclic pyrimidines) as crf receptor antagonists)


RN 268547-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
(CA INDEX NAME)




RN 268547-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 268547-50-8 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)



RN 268547-55-3 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(1-butylpentyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)

10/256,198




RN 268547-68-8 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 374800-50-7 CAPLUS

CN Benzenemethanol, α-[[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

.ACCESSION NUMBER: 2001:247338 CAPLUS
 DOCUMENT NUMBER: 134:280854
 TITLE: Preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors
 INVENTOR(S): Horvath, Raymond F.; Tran, Jennifer; De, Lombaert Stephane; Hodgetts, Kevin Julian; Carpino, Philip A.; Griffith, David A.
 PATENT ASSIGNEE(S): Neurogen Corporation, USA; Pfizer, Inc.; De Lombaert, Stephane
 SOURCE: PCT Int. Appl., 211 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001023389	A2	20010405	WO 2000-US26886	20000929
WO 2001023389	A3	20020510		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG CA 2379640 AA 20010405 CA 2000-2379640 20000929 EP 1224187 A2 20020724 EP 2000-967133 20000929 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL US 6506762 B1 20030114 US 2000-676941 20000929 JP 2003510327 T2 20030318 JP 2001-526541 20000929 NZ 517575 A 20040430 NZ 2000-517575 20000929 BG 106508 A 20030228 BG 2002-106508 20020311 NO 2002001358 A 20020527 NO 2002-1358 20020319 ZA 2002002518 A 20030630 ZA 2002-2518 20020328 US 2003158197 A1 20030821 US 2002-291446 20021108 US 6696445 B2 20040224 US 2004229870 A1 20041118 US 2003-705446 20031110 PRIORITY APPLN. INFO.: US 1999-156870P P 19990930 US 2000-676941 A3 20000929 WO 2000-US26886 W 20000929 US 2002-291446 A3 20021108 OTHER SOURCE(S): MARPAT 134:280854 GI				

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. [I-III, etc.; X = N, CR14; W = S, O, NR15; Y = N, CR3; E, F, G = CR3, N; R1 = H, alkyl, etc.; R2 = H, alkyl, cycloalkyl, etc.; A = (un)substituted (CH2)_m (wherein m = 1-3); A and B form a (un)substituted

carbocycle; A and R2, or B and R2 form (un)substituted aminocarbocycle, aminoheterocycle; B = (un)substituted (CH₂)_n (n = 1-3); R3, R16 = H, alkyl, etc.; R4 = (un)substituted aryl, heteroaryl; R5 = (cycloalkyl)alkyl, alkenyl, etc.; R6 = H, alkyl, etc.] which are potent antagonists at the NPY1 receptor, and are useful in treating physiol. disorders associated with an excess of neuropeptide Y, including eating disorders, such as, for example, obesity and bulimia, and certain cardiovascular diseases, for example, hypertension, were prepared E.g., a multi-step synthesis of IV was described. The compds. I showed K_i of 0.1 nM - 10 μM against NPY1 receptor binding.


IT 332141-79-4P 332141-80-7P 332141-81-8P
 332141-83-0P 332141-89-6P 332141-90-9P
 332141-91-0P 332141-92-1P 332141-97-6P
 332141-98-7P 332141-99-8P 332142-00-4P
 332142-05-9P 332142-06-0P 332142-07-1P
 332142-08-2P 332890-54-7P 332890-58-1P
 332890-63-8P 332890-67-2P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of certain alkylene diamine-substituted heterocycles as NPY1 receptor inhibitors)


RN 332141-79-4 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-80-7 CAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-81-8 CAPLUS
 CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 332141-83-0 CAPLUS
 CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A






RN 332141-89-6 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-90-9 CAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-91-0 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)

PAGE 1-A





PAGE 2-A



RN 332141-92-1 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A






RN 332141-97-6 CAPLUS

CN 1,2-Ethanediamine, N-cyclopentyl-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-98-7 CAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332141-99-8 CAPLUS
 CN 1,2-Ethanediamine, N-[2-(3,4-dimethoxyphenyl)ethyl]-N'-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




RN 332142-00-4 CAPLUS
 CN 1,2-Ethanediamine, N-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 332142-05-9 CAPLUS
 CN 1,2-Ethanediamine, N-cyclopentyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)





RN 332142-06-0 CAPLUS

CN 1,2-Ethanediamine, N-cyclohexyl-N'-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]- (9CI) (CA INDEX NAME)




RN 332142-07-1 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[2-(3,4-dimethoxyphenyl)ethyl]- (9CI) (CA INDEX NAME)




RN 332142-08-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-[1-(2-pyrimidinyl)-4-piperidinyl]- (9CI)
 (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 332890-54-7 CAPLUS
 CN 1,2-Ethanediamine, N-[2,5-dimethyl-3-(2,4,6-trimethylphenyl)-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyran-2-yl)- (9CI) (CA INDEX NAME)



D1-NH-CH₂-CH₂-NH




RN 332890-58-1 CAPLUS

CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-2,5-dimethyl-2H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)




D1-NH-CH₂-CH₂-NH




RN 332890-63-8 CAPLUS

CN 1,2-Ethanediamine, N-[1,5-dimethyl-3-(2,4,6-trimethylphenyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



RN 332890-67-2 CAPLUS
 CN 1,2-Ethanediamine, N-[3-(2,6-dichloro-4-methoxyphenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]-N'-(tetrahydro-2H-pyranyl)- (9CI) (CA INDEX NAME)



L7 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

5094
2914
ACCESSION NUMBER: 2000:335410 CAPLUS

DOCUMENT NUMBER: 132:334475

TITLE: Preparation of tricyclic compounds as CRF receptor antagonists

INVENTOR(S): Haddach, Mustapha; Nelson, Jodie; Dyck, Brian P.; Guo, Zhiqiang; Huang, Charles Q.; Mccarthy, James R.

PATENT ASSIGNEE(S): Neurocrine Biosciences, Inc., USA

SOURCE: PCT Int. Appl., 123 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000027846	A2	20000518	WO 1999-US27054	19991112
WO 2000027846	A3	20001116		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2350642	AA	20000518	CA 1999-2350642	19991112
BR 9915130	A	20010807	BR 1999-15130	19991112
EP 1129091	A2	20010905	EP 1999-960363	19991112
EP 1129091	B1	20021002		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO			
AT 225349	E	20021015	AT 1999-960363	19991112
AU 755552	B2	20021212	AU 2000-17258	19991112
NZ 510955	A	20030131	NZ 1998-510955	19991112
ES 2180338	T3	20030201	ES 1999-960363	19991112
PT 1129091	T	20030228	PT 1999-960363	19991112
NO 2001002194	A	20010503	NO 2001-2194	20010503
ZA 2001004441	A	20020530	ZA 2001-4441	20010530
HK 1038926	A1	20030718	HK 2002-100690	20020129
PRIORITY APPLN. INFO.:			US 1998-191073	A 19981112
			US 1999-370837	A 19990809
			US 1999-401364	A 19990921
			WO 1999-US27054	W 19991112
OTHER SOURCE(S):	MARPAT 132:334475			
GI				




AB The title compds. [I; n = 1-2; A, C = N, C, CH; B = N, CR3; with the provisos that at least one of A, B and C = N; A, B and C are not all N; and either A-B or B-C is a double bond; X = N, CH; Ar = (un)substituted aryl, heteroaryl; R = alkyl, alkylidenyl, arylalkyl, heteroarylalkyl; m = 0-3; R1 = C(H)0,1R4R5, SO2R5; R2 = H, alkyl; R3 = H, alkyl, haloalkyl; R4 = H, alkyl, halo, etc.; R5 = -YZR6; (un)substituted alkanediyl, a direct bond; Z = NH, O, S, etc.; R6 = H, alkyl, aryl, etc.] which have utility in the treatment of a variety of disorders, including the treatment of disorders manifesting hypersecretion of CRF in a warm-blooded animals, such as stroke, depression, and anxiety, were prepared E.g., a multi-step synthesis of II which showed Ki of < 250 nM against CRF receptor binding, was given.

IT 268547-48-4P 268547-49-5P 268547-50-8P
268547-55-3P 268547-68-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of tricyclic compds. as CRF receptor antagonists)


RN 268547-48-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-ol, 3-(2,4-dichlorophenyl)-5-methyl- (9CI)
(CA INDEX NAME)




RN 268547-49-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 268547-50-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-5-methyl-N-(1-propylbutyl)- (9CI) (CA INDEX NAME)




RN 268547-55-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(1-butylpentyl)-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)



RN 268547-68-8 CAPLUS

CN 1-Pentanol, 2-[[3-(2,4-dichlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)



L7 ANSWER 13 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1999:576926 CAPLUS

DOCUMENT NUMBER: 131:199695

TITLE: Preparation of pyrazolo[4,3-b]pyridines as corticotropin releasing factor receptor antagonists.

INVENTOR(S): Chen, Chen; Wilcoxon, Keith M.; Huang, Charles Q.; Haddach, Mustapha; McCarthy, James R.

PATENT ASSIGNEE(S): Janssen Pharmaceutica N.V., Belg.; Neurocrine Biosciences, Inc.

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9945007	A1	19990910	WO 1999-EP1307	19990226
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9929310	A1	19990920	AU 1999-29310	19990226
ZA 9901767	A	20001011	ZA 1999-1767	19990304
US 6613777	B1	20030902	US 2001-623634	20010220
US 2004121999	A1	20040624	US 2003-650474	20030828
PRIORITY APPLN. INFO.:			US 1998-77311P	P 19980306
			WO 1999-EP1307	W 19990226
			US 2001-623634	A1 20010220
OTHER SOURCE(S):	MARPAT 131:199695			
GI				



AB Use of title compds. [I; R1 = alkyl, NR5R6, OR6, SR6; R2 = alkyl, alkoxy, alkylthio; R3 = Ar1, Het1; R4 = H, alkyl; R5 = H, alkyl, mono- or di(cycloalkyl)methyl, cycloalkyl, alkenyl, hydroxyalkyl, alkylcarbonyloxyalkyl, mono- or di(alkyl)aminoalkyl, alkoxyalkyl; R6 = alkyl, mono- or di(cycloalkyl)methyl, Ar2alkyl, Ar2oxyalkyl, alkoxyalkyl, hydroxyalkyl, alkenyl, thienylmethyl, furanylmethyl, tetrahydrofuranylmethyl, alkylthioalkyl, mono- or di(alkyl)aminoalkyl, di(alkyl)amino, alkylcarbonylalkyl; R5R6N = pyrrolidinyl, piperidinyl,


homopiperidinyl, morpholinyl, thiomorpholinyl; Ar1, Ar2 = (substituted) Ph, naphthyl; Het1 = (substituted) pyridinyl], for treatment of conditions arising from hypersecretion of corticotropin releasing factor is claimed. I (synthetic schemes given) showed CRF receptor binding ability with $K_i \leq 250$ nM.

IT 242128-80-9P 242128-81-0P 242128-82-1P
 242128-83-2P 242128-84-3P 242128-85-4P
 242128-86-5P 242128-87-6P 242128-88-7P
 242128-89-8P 242128-90-1P 242128-91-2P
 242128-92-3P 242128-93-4P 242128-94-5P
 242128-95-6P 242128-96-7P 242128-97-8P
 242128-98-9P 242128-99-0P 242129-00-6P
 242129-01-7P 242129-02-8P 242129-03-9P
 242129-04-0P 242129-05-1P 242129-06-2P
 242129-07-3P 242129-08-4P 242129-09-5P
 242129-10-8P 242129-11-9P 242129-12-0P
 242129-13-1P 242129-14-2P 242129-15-3P
 242129-16-4P 242129-17-5P 242129-18-6P
 242129-19-7P 242129-20-0P 242129-21-1P
 242129-22-2P 242129-23-3P 242129-24-4P
 242129-25-5P 242129-26-6P 242129-27-7P
 242129-28-8P 242129-29-9P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of pyrazolo[4,3-b]pyridines as CRF receptor antagonists)


RN 242128-80-9 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 242128-81-0 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)



RN 242128-82-1 CAPLUS


10/256,198

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-1,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242128-83-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N,N-bis(2-methoxyethyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242128-84-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N-(2-methoxyethyl)-N,1,5-trimethyl- (9CI) (CA INDEX NAME)




RN 242128-85-4 CAPLUS

CN Ethanol, 2-[[3-(2,4-dichlorophenyl)-1,5-dimethyl-1H-pyrazolo[4,3-b]pyridin-7-yl]propylamino]- (9CI) (CA INDEX NAME)




RN 242128-86-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2,4-dichlorophenyl)-N,1,5-trimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242128-87-6 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 242128-88-7 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242128-89-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242128-90-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242128-91-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-1-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242128-92-3 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-2-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242128-93-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-1-propyl- (9CI) (CA INDEX NAME)



RN 242128-94-5 CAPLUS


CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-2-propyl- (9CI) (CA INDEX NAME)



10/256,198


RN 242128-95-6 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-1-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 242128-96-7 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2,4-dichlorophenyl)-5-methyl-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 242128-97-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242128-98-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242128-99-0 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-2,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)



RN 242129-00-6 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-dichlorophenyl)-1-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)



RN 242129-01-7 CAPLUS


CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-(cyclopropylmethyl)-3-(2,4-

dichlorophenyl)-2-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-02-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-03-9 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N-ethyl-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-04-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N,1-diethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-05-1 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2,4-dichlorophenyl)-N,2-diethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-06-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methylphenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-07-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2-chloro-4-methylphenyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-08-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2-chloro-4-methylphenyl)-N-ethyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-09-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methylphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-10-8 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(cyclopropylmethyl)-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-11-9 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methylphenyl)-1-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-12-0 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4-methylphenyl)-2-ethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-13-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(cyclopropylmethyl)-1-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-14-2 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(cyclopropylmethyl)-2-ethyl-5-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-15-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-ethyl-N-(3-methoxypropyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-16-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-1,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242129-17-5 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-ethyl-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-18-6 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-1,5-dimethyl-N-(1-methylpropyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-19-7 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4-methylphenyl)-N-(cyclopropylmethyl)-1,5-dimethyl-N-propyl- (9CI) (CA INDEX NAME)




RN 242129-20-0 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4,6-dimethylphenyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-21-1 CAPLUS

CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-3-(2-chloro-4,6-dimethylphenyl)-2,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-22-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2-chloro-4,6-dimethylphenyl)-N-ethyl-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-23-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2-chloro-4,6-dimethylphenyl)-N,1-diethyl-5-methyl- (9CI) (CA INDEX NAME)




RN 242129-24-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, N-butyl-3-(2-chloro-4,6-dimethylphenyl)-N-(cyclopropylmethyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-25-5 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chloro-4,6-dimethylphenyl)-N,N-bis(2-methoxyethyl)-1,5-dimethyl- (9CI) (CA INDEX NAME)




RN 242129-26-6 CAPLUS
 CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 3-(2-chlorophenyl)-2,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)




RN 242129-27-7 CAPLUS
 CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, 2,5-dimethyl-3-phenyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 242129-28-8 CAPLUS
 CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 3-[2,4-bis(trifluoromethyl)phenyl]-1,5-dimethyl-N,N-dipropyl- (9CI) (CA INDEX NAME)



RN 242129-29-9 CAPLUS
 CN 2H-Pyrazolo[4,3-b]pyridin-7-amine, N,N-dibutyl-2,5-dimethyl-3-(2,4,6-trimethylphenyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 14 OF 14 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 1988:112444 CAPLUS

DOCUMENT NUMBER: 108:112444

TITLE: Preparation of pyrazolo[4,3-b]pyridinamines as antiinflammatories

INVENTOR(S): Markwell, Roger Edward; Ward, Robert William; De Mello, Carol Rachel

PATENT ASSIGNEE(S): Beecham Group PLC, UK

SOURCE: Eur. Pat. Appl., 42 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 239191	A2	19870930	EP 1987-300631	19870126
EP 239191	A3	19880720		
R: BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DK 8700462	A	19870731	DK 1987-462	19870128
AU 8768057	A1	19870806	AU 1987-68057	19870128
ZA 8700619	A	19880224	ZA 1987-619	19870128
US 4833136	A	19890523	US 1987-8267	19870129
JP 62240682	A2	19871021	JP 1987-18793	19870130
PRIORITY APPLN. INFO.:			GB 1986-2236	A 19860130
			GB 1986-8918	A 19860411

GI



AB The title compds. [I; R = H, C1-6 alkyl; R1 = H, alkanoyl, cyano, (un)modified CO₂H, (un)substituted alkyl; R2 = R1, (un)substituted Ph; R1R2 = (alkyl-substituted) (CH₂)₃₋₆; R3 = H, alkanoyl, C2-10 alkenyl, (un)modified CO₂H, (un)substituted C1-10 alkyl, C3-10 cycloalkyl, Ph; RR3 = (CH[2]4-6; R4 = H, C1-4 alkyl, (un)substituted Ph, PhCH₂; R5 = C1-6 alkyl, amino, halo, NO₂, thienyl, furyl, (1-alkyl)pyrrolyl, (un)substituted Ph, PhCH₂] and their salts were prepared as antiinflammatories, especially useful for topical application.

3-Methylpyrazole

was nitrated after protection by arylation with 2,4-(O₂N)C₆H₃F, and the resulting 3-methyl-4-nitropyrazole was converted in 3 steps to chlorodimethylpyrazolopyridine II (R₆ = Cl). The latter was refluxed with HOCH₂CH₂NH₂ in xylene to give II (R₆ = HOCH₂CH₂NH) (III). In the topical mouse ear assay, 500 µg III applied to the ear gave 86% inhibition of cantharidin-induced inflammation.

IT 113140-16-2P 113140-23-1P 113140-25-3P

113140-26-4P 113140-28-6P 113140-29-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT

(Reactant or reagent)

(preparation and aminolysis of)


RN 113140-16-2 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-5-methyl-3-phenyl- (9CI) (CA INDEX NAME)




RN 113140-23-1 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(4-chlorophenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 113140-25-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(3-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 113140-26-4 CAPLUS


CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(4-methoxyphenyl)-5-methyl- (9CI) (CA INDEX NAME)




RN 113140-28-6 CAPLUS
CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-5-methyl-3-(2-thienyl)- (9CI) (CA INDEX NAME)



RN 113140-29-7 CAPLUS
CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-5-methyl-3-(3-thienyl)- (9CI) (CA INDEX NAME)



IT **113140-24-2P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 113140-24-2 CAPLUS
CN 1H-Pyrazolo[4,3-b]pyridine, 7-chloro-3-(2-methoxyphenyl)-5-methyl- (9CI)
(CA INDEX NAME)



IT **113139-96-1P 113139-98-3P 113139-99-4P**


113140-00-4P 113140-01-5P 113140-05-9P

113140-07-1P 113165-08-5P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as topical antiinflammatory)


RN 113139-96-1 CAPLUS

CN Ethanol, 2-[(5-methyl-3-phenyl-1H-pyrazolo[4,3-b]pyridin-7-yl)amino]-
(9CI) (CA INDEX NAME)




RN 113139-98-3 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 5-methyl-3-phenyl-N-2-propenyl- (9CI)
(CA INDEX NAME)




RN 113139-99-4 CAPLUS

CN Ethanol, 2-[[3-(4-chlorophenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 113140-00-4 CAPLUS

CN 1H-Pyrazolo[4,3-b]pyridin-7-amine, 5-methyl-N-(2-methylpropyl)-3-phenyl-
(9CI) (CA INDEX NAME)




RN 113140-01-5 CAPLUS

CN Ethanol, 2-[[3-(3-methoxyphenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)




RN 113140-05-9 CAPLUS

CN Ethanol, 2-[[5-methyl-3-(2-thienyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)



RN 113140-07-1 CAPLUS


CN Ethanol, 2-[[3-(4-methoxyphenyl)-5-methyl-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)





RN 113165-08-5 CAPLUS

CN Ethanol, 2-[[5-methyl-3-(3-thienyl)-1H-pyrazolo[4,3-b]pyridin-7-yl]amino]- (9CI) (CA INDEX NAME)

10/256,198





chain nodes :

12

ring nodes :

1 2 3 4 5 6 7 8 9

ring/chain nodes :

10 11

chain bonds :

4-10 6-11 7-12

ring bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 5-6 7-8 8-9

exact/norm bonds :

1-2 1-6 2-3 2-7 3-4 3-9 4-5 4-10 5-6 6-11 7-8 7-12 8-9

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS 11:CLASS
12:Atom

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.